BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the appointment of Jinky Ang Rosselli as chief data and insights officer.
In this new role, Ms. Rosselli will lead a global team to leverage and build the company’s data science, analytics and insights infrastructure, helping inform strategic decision making at BioCryst. In her new role, Ms. Rosselli will join the BioCryst leadership team and report directly to Jon Stonehouse, chief executive officer of BioCryst.
“Jinky’s ability to employ traditional and non-traditional methods to insight gathering, evidence generation and data science has proven to be a critical competitive advantage for BioCryst. Her thoughtful and disciplined synthesis of insights and data has allowed us to confidently understand the ORLADEYO® (berotralstat) market opportunity, helped inform the build of an optimal commercial infrastructure and has fueled our strong launch performance. We look forward to broadening the impact of her work to deliver even more value across the company with this new role,” Stonehouse said.
Ms. Rosselli joined BioCryst in 2015 as vice president of global business analysis and operations. Prior to joining BioCryst, Ms. Rosselli led the global business intelligence and insight team at United Therapeutics from 2011 to 2015. Prior to United Therapeutics, she spent over four and a half years in marketing analytics and marketing roles at Talecris Biotherapeutics (now Grifols). Prior to Talecris, Ms. Rosselli spent five years in a variety of market research and analytics roles at Novartis.
“BioCryst’s rigorous, no-fear approach to data and insights truly differentiates us as a company. We are not only fully anchored in the integrity of data, but believe strongly in the importance of humanizing data in the right context, a truly holistic approach. It has been exciting to experience the transformation of unfiltered insights into action through the launch of ORLADEYO. The team is already working aggressively to optimize and repeat this success across multiple complement-mediated diseases and other pipeline opportunities,” Rosselli said.
Ms. Rosselli received a B.S. in cognitive and behavioral psychology from Duke University and a master’s in public health from the Yale University School of Medicine. She is a Fulbright Scholar and Presidential Leadership Scholar. She currently serves on the board of directors of two non-profit organizations, Triangle Residential Options for Substance Abusers (TROSA) and the Durham Medical Orchestra Foundation.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize ORLADEYO, which could take longer or be more expensive than planned; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; ongoing and future preclinical and clinical development of BCX9930, BCX9250 and galidesivir may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA, EMA, PMDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.
+1 919 859 7910
Catherine Collier Kyroulis
+1 917 886 5586